Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,940
  • Shares Outstanding, K 58,665
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,290 K
  • 60-Month Beta 2.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +45.71%
on 01/31/20
6.31 -35.34%
on 02/19/20
+1.15 (+39.25%)
since 01/27/20
3-Month
2.25 +81.33%
on 12/03/19
6.31 -35.34%
on 02/19/20
+1.72 (+72.88%)
since 11/27/19
52-Week
2.10 +94.29%
on 02/28/19
6.31 -35.34%
on 02/19/20
+1.85 (+82.96%)
since 02/27/19

Most Recent Stories

More News
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX(R)2-73 (blarcamesine) in Multiple Sclerosis (MS)

Published in Journal of Neuroimmunology, Results Highlight ANAVEX(R)2-73 (blarcamesine) Shown to Protect and Repair Myelin Forming Cells

AVXL : 4.09 (+0.49%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

BAYRY : 18.5630 (-1.37%)
RARE : 55.55 (-0.29%)
AVXL : 4.09 (+0.49%)
GH : 81.11 (-0.48%)
Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

ONCY : 2.22 (-3.90%)
TRVN : 0.68 (-2.86%)
AVXL : 4.09 (+0.49%)
GH : 81.11 (-0.48%)
Anavex Life Sciences Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Anavex Life Sciences Corp. (NASDAQ:AVXL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on February 6, 2020...

AVXL : 4.09 (+0.49%)
Anavex Life Sciences: Fiscal 1Q Earnings Snapshot

NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Thursday reported a loss of $6.6 million in its fiscal first quarter.

AVXL : 4.09 (+0.49%)
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.09 (+0.49%)
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.09 (+0.49%)
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX(R)2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.09 (+0.49%)
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?

Is (AVXL) Outperforming Other Medical Stocks This Year?

AVXL : 4.09 (+0.49%)
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.09 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AVXL with:

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

2nd Resistance Point 4.58
1st Resistance Point 4.33
Last Price 4.10
1st Support Level 3.89
2nd Support Level 3.70

See More

52-Week High 6.31
Fibonacci 61.8% 4.70
Fibonacci 50% 4.20
Last Price 4.10
Fibonacci 38.2% 3.71
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar